Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 8/20 | 0.37 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL429669 | 0.91 | CHEK1 (0.38) | MAPKAPK2PARP1 | |
| SCHEMBL426031 | 0.85 | CHEK1 (0.40) | MAPKAPK2HDAC1 | |
| SCHEMBL426049 | 0.85 | CHEK1 (0.39) | MAPKAPK2F10 | |
| SCHEMBL424677 | 0.84 | MAPKAPK2 (0.51) | MAPKAPK2 | |
| SCHEMBL427333 | 0.83 | MAPKAPK2 (0.39) | MAPKAPK2 | |
| SCHEMBL429718 | 0.83 | MAPKAPK2 (0.39) | MAPKAPK2 | |
| SCHEMBL431329 | 0.82 | MAPKAPK2 (0.50) | MAPKAPK2 | |
| SCHEMBL427353 | 0.81 | MAPKAPK2 (0.37) | MAPKAPK2 | |
| SCHEMBL430059 | 0.81 | MAPKAPK2 (0.41) | MAPKAPK2 | |
| SCHEMBL429140 | 0.81 | MAPKAPK2 (0.59) | MAPKAPK2LCKFLT3JAK2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2012-01-26 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| CN-101687869-A | Tetracyclic lactam derivatives as MK2 inhibitors | NOVARTIS AG | 2010-03-31 | — | — | CN | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | MAP3K11 557/4885MAPKAPK2 480/4885PARP1 1748/4885 |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | MAP3K11 557/4885MAPKAPK2 480/4885PARP1 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.